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CLINICAL STUDIES FOR BIOMARKER VALIDATION IN 
OSTEOARTHRITIS 
Michael C Nevitt 
Validated biochemical and imaging biomarkers for osteoarthritis 
(OA) are needed to help speed drug discovery and reduce bot- 
tlenecks in OA treatment evaluation by streamlining and support- 
ing early phase clinical and proof of concept studies. There are 
many potential uses for biomarkers, ranging from understand- 
ing OA etiology and pathogenesis to predicting and monitoring 
the outcome of treatments in individual patients; a diverse spec- 
trum of potential candidates are emerging to meet these needs. 
Candidate biomarkers range from molecular markers that re- 
flect the of synthesis and degradation of joint tissues (e.g. car- 
tilage matrix molecule fragments) or factors that influence these 
processes (e.g. cytokines, proteases), imaging markers that re- 
flect changes in tissue composition (e.g. dGEMRIC) or the out- 
come of pathologic processes on joint tissue morphology (e.g. 
MRI cartilage volume), and susceptibility markers that reflect the 
risk of onset and progression of disease (e.g. genetic markers). 
For biomarkers that have demonstrated acceptable technical per- 
formance (e.g. reliability, precision, dynamic range) the studies 
needed for clinical validation depend, in part, on the purposes of 
the biomarker. Diagnostic markers (disease/no disease) can be 
validated in cross-sectional or case-control studies. Validation of 
predictive or prognostic biomarkers requires longitudinal clinical 
outcome studies. Although such studies allow evaluation of as- 
sociations between baseline levels of, or changes in, biomarkers 
and contemporaneous clinical changes, this type of data is in- 
sufficient o establish the ability of a biomarker to predict, or cor- 
relate with, treatment outcomes. This requires randomized clin- 
ical trials of treatments that demonstrate a clinically meaning- 
ful treatment effect, so that the ability of a baseline measure to 
predict outcomes, and of changes in a marker to track with out- 
comes, can be evaluated. RCTs of disease modifying OA treat- 
ments should ideally include a variety of imaging modalities and 
adequate stored biospecimens to support both biomarker discov- 
ery and validation. In the absence of effective treatments for OA, 
clinical validation of biomarkers will be confined to longitudinal 
observational studies and RCTs that have failed to show a treat- 
ment effect. These should investigate well-defined groups of pa- 
tients with OA, with measurements at multiple time-points of joint 
symptoms and disability, joint imaging, body fluid specimens for 
molecular marker measurement and risk factors. Clinical stud- 
ies of persons with established OA are already yielding useful 
insights into biomarkers for assessing and predicting progression 
of clinical disease. Validation of diagnostic, prognostic and surro- 
gate markers useful in identifying, preventing and treating early or 
preclinical disease requires longitudinal studies in subjects who 
do not have overt clinical OA, but are at risk of developing it. Since 
the most important outcome from a prevention standpoint is the 
onset of clinically significant disease, these studies need to be 
large and long enough, and sufficiently enriched with those at 
risk of developing OA, to yield adequate numbers of new cases 
of clinical disease. 
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THE OSTEOARTHRITIS INITATIVE: WHERE DO WE GO 
FROM HERE? 
GE Lester 
The Osteoarthritis Initiative (OAI) is a longitudinal cohort study 
coordinated by the National Institute on Aging (NIA) and the Na- 
tional Institute on Arthritis and Musculoskeletal and Skin Dis- 
eases (NIAMS) and supported by a public-private partnership 
designed to create a public resource to validate prospective 
biomarkers for diagnosis and monitoring of osteoarthritis. The 
project was initiated in July 2002 and recruitment and enrollment 
of the cohort began in late winter 2004. Currently, there are over 
3500 subjects enrolled in the cohort, which is expected to num- 
ber 4200 by the end of recruitment. One-year follow up measure- 
ments were begun in spring 2005 and to date over 800 have 
been carried out. The cohort contains individuals (60% female) 
with early OA or at high risk of developing OA. The ratio of these 
two groups is 1:2.5. There is a small (<200 subjects) sub-group 
of individuals with no risk of OA or radiologic signs of knee joint 
changes. The clinical data, images, and biospecimens from these 
subjects make up the research resource of the OAI. Within the 
next 3 months, the data from the initial 2500 subjects enrolled in 
the OAI will be available for use by the research community at 
large on the OAI Online website. The purpose of the web site is 
to facilitate data and image sharing, to make it easy for users to 
identify and retrieve data for analysis, and to encourage use of 
the OAI data and images. The clinical data web site will contain 
search and browse variable documentation to allow users to cre- 
ate custom codebooks, to explore data online, and to download 
data as SAS datasets for further analysis. Initial release of images 
will be more limited. There will be pre-made DVDs for distribution 
upon request that contain images from 200 OAI subjects, 100 
from the progression cohort and 100 from the incidence cohort 
selected randomly. Images from all 2000 subjects will be avail- 
able to those users who need them. Access to these images will 
require the submission of a hard drive with 1-2 tarabyte capacity 
for the download. There will be some central image assessment 
done within the OAI. This will include assessment of baseline and 
follow up readings of knee x-rays (KL scores and joint space width 
change), cartilage volume calculations, and readings of baseline 
hand and hip x-rays. As follow up data are accrued, these will be 
added to the data set and linked to the baseline data. Collabo- 
rative and ancillary projects related to data analysis or additions 
to the existing protocol will also be considered by the OAI Steer- 
ing Committee. NIH has plans for future meetings and initiatives 
that will relate to the use and analysis of this research resource. 
These will be announced as funds become available. It is hoped 
that investigators will take advantage of this resource and use 
it as the basis for testing new and novel hypotheses concerning 
osteoarthritis diagnosis, onset, and progression. 
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THE OSTEOARTHRITIS INITATIVE MR PILOT STUDIES 
E Schneider 
The goal of the Osteoarthritis Initiative (OAI) is to create a pub- 
lic database to validate prospective biomarkers, including radio- 
graphic and Magnetic Resonance (MR) images. To ensure the 
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